This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tiret, L. Search for Related Content PubMed PubMed Citation Articles by Tiret, L.

CLINICAL STUDIES

Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy

The CARDIGENE study

Laurence Tiret, PhD^*, Christine Mallet, MSc, Odette Poirier, PhD^*, Viviane Nicaud, MA^*, Alain Millaire, MD, PhD, Jean-Brieuc Bouhour, MD, G.érard Roizès, PhD^||, Michel Desnos, MD^¶, Richard Dorent, MD^#, Ketty Schwartz, PhD, François Cambien, MD^*, Michel Komajda, MD^** for the CARDIGENE Group

^* INSERM U525, Paris, France
INSERM SC7, Paris, France
CHR de Lille, Lille, France
CHR de Nantes, Nantes, France
^|| INSERM U249, Montpellier, France
^¶ Hôpital Boucicaut, Paris, France
^# Service de Chirurgie Cardiaque, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
^** Service de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
INSERM U523, Paris, France

Manuscript received February 19, 1999; revised manuscript received July 29, 1999, accepted October 5, 1999.

Reprint requests and correspondence: Dr. Laurence Tiret, INSERM U525, 17 rue du Fer à Moulin, 75005 Paris, France
tiret{at}idf.inserm.fr

OBJECTIVES

The study investigated the potential role of eight candidate genes in the susceptibility to idiopathic dilated cardiomyopathy (IDC).

BACKGROUND

Idiopathic dilated cardiomyopathy has a familial origin in 20% to 25% of cases, and several genetic loci have been identified in rare monogenic forms of the disease. These findings led to the hypothesis that genetic factors might also be involved in sporadic forms of the disease. In complex diseases that do not exhibit a clear pattern of familial aggregation, the candidate gene approach is a strategy widely used to identify susceptibility genes. All genes coding for proteins involved in biochemical or physiological abnormalities of cardiac function are potential candidates for IDC.

METHODS

We studied 433 patients with IDC and 401 gender- and age-matched controls. Polymorphisms investigated were the I/D polymorphism of the angiotensin I-converting enzyme (ACE) gene, the T174M and M235T polymorphisms of the angiotensinogen (AGT) gene, the A-153G and A+39C polymorphisms of the angiotensin-II type 1 receptor (AGTR1) gene, the T-344C polymorphism of the aldosterone synthase (CYP11B2) gene, the G-308A polymorphism of the tumor necrosis factor-alpha (TNF) gene, the R25P polymorphism of the transforming growth factor beta₁ (TGFB1) gene, the G+11/in23T polymorphism of the endothelial nitric oxide synthase (NOS3) gene and the C-1563T polymorphism of the brain natriuretic peptide (BNP) gene.

RESULTS

None of the polymorphisms were significantly associated with the risk or the severity of the disease.

CONCLUSIONS

We did not find evidence for an involvement of any of the 10 investigated polymorphisms in the susceptibility to IDC.

Abbreviations and Acronyms   ACE = angiotensin I-converting enzyme   AGT = angiotensinogen   AGTR1 = angiotensin-II type 1 receptor   BNP = brain natriuretic peptide   CYP11B2 = aldosterone synthase   DCM = dilated cardiomyopathy   IDC = idiopathic dilated cardiomyopathy   NOS3 = endothelial nitric oxide synthase   TGFB1 = transforming growth factor beta1   TNF = tumor necrosis factor-alpha

This article has been cited by other articles:

				C. Vassalle and M. G. Andreassi Genetic Polymorphisms of the Natriuretic Peptide System in the Pathogenesis of Cardiovascular Disease: What Lies on the Horizon? Clin. Chem., May 1, 2009; 55(5): 878 - 887. [Abstract] [Full Text] [PDF]

				D. D. Schocken, E. J. Benjamin, G. C. Fonarow, H. M. Krumholz, D. Levy, G. A. Mensah, J. Narula, E. S. Shor, J. B. Young, and Y. Hong Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, May 13, 2008; 117(19): 2544 - 2565. [Abstract] [Full Text] [PDF]

				W. Koch, W. Latz, M. Eichinger, C. Ganser, A. Schomig, and A. Kastrati Genotyping of the Angiotensin I-Converting Enzyme Gene Insertion/Deletion Polymorphism by the TaqMan Method Clin. Chem., August 1, 2005; 51(8): 1547 - 1549. [Full Text] [PDF]

				N. G. Mahon, R. T. Murphy, C. A. MacRae, A. L.P. Caforio, P. M. Elliott, and W. J. McKenna Echocardiographic Evaluation in Asymptomatic Relatives of Patients with Dilated Cardiomyopathy Reveals Preclinical Disease Ann Intern Med, July 19, 2005; 143(2): 108 - 115. [Abstract] [Full Text] [PDF]

				I. Cascorbi, M. Paul, and H. K. Kroemer Pharmacogenomics of heart failure - focus on drug disposition and action Cardiovasc Res, October 1, 2004; 64(1): 32 - 39. [Abstract] [Full Text] [PDF]

				W. Huang, C. Xie, H. Zhou, T. Yang, and M. Sun Association of the angiotensin-converting enzyme gene polymorphism with chronic heart failure in Chinese Han patients Eur J Heart Fail, January 1, 2004; 6(1): 23 - 27. [Abstract] [Full Text] [PDF]

				P. A. Doevendans Genetic Polymorphisms and Cardiac Failure Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 23 - 29. [PDF]

				M. Alikasifoglu, L. Tokgozoglu, T. Acil, E. Atalar, M. A. Oto, S. S. Kes, and E. Tuncbilek Tumor necrosis factor-{alpha} polymorphism in Turkish patients with dilated cardiomyopathy Eur J Heart Fail, March 1, 2003; 5(2): 161 - 163. [Full Text] [PDF]

				E Takai, H Akita, K Kanazawa, N Shiga, M Terashima, Y Matsuda, C Iwai, Y Miyamoto, H Kawai, A Takarada, et al. Association between aldosterone synthase (CYP11B2) gene polymorphism and left ventricular volume in patients with dilated cardiomyopathy Heart, December 1, 2002; 88(6): 649 - 650. [Full Text] [PDF]

				A. D. Tiago, D. Badenhorst, D. Skudicky, A. J. Woodiwiss, G. P. Candy, R. Brooksbank, K. Sliwa, P. Sareli, and G. R. Norton An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy Cardiovasc Res, June 1, 2002; 54(3): 584 - 589. [Abstract] [Full Text] [PDF]

				D. M. McNamara, R. Holubkov, K. Janosko, A. Palmer, J. J. Wang, G. A. MacGowan, S. Murali, W. D. Rosenblum, B. London, and A. M. Feldman Pharmacogenetic Interactions Between {beta}-Blocker Therapy and the Angiotensin-Converting Enzyme Deletion Polymorphism in Patients With Congestive Heart Failure Circulation, March 27, 2001; 103(12): 1644 - 1648. [Abstract] [Full Text] [PDF]

				M KOMAJDA Genetics of dilated cardiomyopathy: a molecular maze? Heart, November 1, 2000; 84(5): 463 - 464. [Full Text]